Etiometry Board of Directors
Shane Cooke | Board Member, President and CEO
Shane Cooke joined Etiometry in 2019 as President & CEO, bringing over 19 years of experience in the medical device and pharmaceutical market spaces in a variety of sales, marketing, strategy and portfolio management roles.
Before joining Etiometry, Shane spent 5+ years as Chief Strategy Officer of Cheetah Medical, which was acquired by Baxter International in 2019. Prior to Cheetah, Shane spent 11 years with Covidien in the patient care, vascular therapies and corporate sectors, with positions such as: corporate strategy, market and competitive intelligence, leading the market development center of excellence and leading strategy efforts for Japan, Europe, Australia and Canada. Shane holds a BA in psychology from the University of Rochester, as well as an MBA from Suffolk University.
Evan Butler | Board Member, COO and Co-founder
Evan Butler is an engineer and entrepreneur who co-founded Etiometry in 2010. Previously, he worked at Boston Children’s Hospital in the Pediatric Cardiac Bioengineering Laboratory designing, building, and testing novel surgical robots and tools. Evan was also a NASA GSRP Fellow with Dryden Flight Research Center, and created intelligent flight control systems.
He received his Bachelor’s degree in Physics and Aerospace Engineering, and his Masters degree in Dynamics and Control Engineering from Boston University. Evan has published conference papers, journal articles and a book chapter in the fields of medical predictive analytics, concentric tube robots and tools for minimally-invasive beating heart surgery, and intelligent flight control systems. Evan has received multiple awards, including the 2010 IEEE Transactions on Robotics Best Paper Award.
Guy Lyndon Fish, MD, MBA | Board Member
Dr. Fish is a seasoned Health Care veteran whose experience spans drugs, devices, health care IT, diagnostics and services by virtue of 25 years in health care venture capital, consulting, and equity markets. With a background in biochemistry and the practice of Internal Medicine, Guy has been a major player in notable successful partnerships, mergers, and post-merger integrations on the global scale, and in development, fundraising, and commercialization for venture backed enterprises.
Dr. Fish is a seasoned Health Care veteran whose experience spans drugs, devices, health care IT, diagnostics and services by virtue of 25 years in health care venture capital (Fletcher Spaght Ventures), consulting (BCG, Fletcher Spaght Inc.), and equity markets (Sanford Bernstein). His degrees in biochemistry from Harvard, and an MD from Yale led to the practice of Internal Medicine, followed by a Yale MBA. Guy has been a major player in notable successful partnerships, mergers, and post-merger integrations on the global scale, and in development, fundraising, and commercialization for venture backed enterprises.
Gregory S. Martin | Board Member
Gregory S. Martin is currently Chief Executive Officer and President of Shamrock Holdings, Inc., a diversified private investment company wholly-owned by the Roy E. and Patricia A. Disney Family.
Since its formation, Shamrock, located in Burbank, California, has managed public securities investments and private equity and real estate transactions with an aggregate value in excess of $3 billion.
Prior to joining Shamrock, Mr. Martin served as General Manager and Director of Operations of an automotive parts company and as a Certified Public Accountant at Price Waterhouse LLP practicing in the firm’s Audit and Assurance Practice and later in its Consulting/Transaction Group.
Mr. Martin currently serves in various capacities on several Boards of Directors, including the Boards of Ionetix Corporation, Etiometry, Inc., Evolved By Nature and A.S. Roma S.p.A. Mr. Martin has also served on the Board of Trustees of Childrens Hospital Los Angeles and of Court Appointed Special Advocates of Orange County.
David Shepherd | Board Member
Mr. Shepherd is a Managing Member, Co-Chief Executive Officer, and co-owner of the Investment Manager, with primary responsibility for the Institutional Advisory Practice. As Co-Chief Executive Officer, Mr. Shepherd oversees the firm’s investment research and fiduciary consulting resources. He also heads the firm’s proprietary systems development strategy alongside SKK’s in-house technology team. Mr. Shepherd co-chairs the firm’s Investment Committee and works closely with the Research Committee.
Mr. Shepherd has decades of experience in investment research, product development and consulting to the pension, endowment and foundation and family office marketplace. He advises the Investment Committees of numerous corporations on investment policy design, monitoring regimens and fiduciary compliance. Mr. Shepherd is also a frequent public speaker, discussing risk and investment management and fiduciary governance. Mr. Shepherd’s focus since co-founding Shepherd Kaplan. LLC in 1998 has been on innovation. Specifically, on providing greater transparency and control to institutions and high-net-worth families in the investment consulting and wealth management space. He holds a degree in Economics and Finance from Boston University.
Etiometry Advisory Board
Dr. Peter Laussen, MB.BS., FANZCA, FCICM | Scientific Advisor
Dr. Peter Laussen is the lead inventor of the T3 platform. He initiated this work in 2009 when he was at Boston Children’s Hospital as the Chief of the Division of Cardiac Critical Care and Professor of Anesthesia at Harvard University. Support for the development of T3 came from the DD Hansen Chair in Pediatric Anesthesia and the Departments of Cardiology and Anesthesia at BCH. In 2012, Peter moved to Toronto as the Chief of the Department of Critical Care Medicine at the Hospital for Sick Children, Professor of Anaesthesia at the University of Toronto, and as the David and Stacey Cynamon Chair in Critical Care Medicine. He is a full time intensive care physician, specializing in children with heart disease, and is co-Chair of the Machine Learning for Healthier Kids steering committee. T3 was installed in the DCCM at Sickkids where Peter has continued to review, refine and extend the performance of the platform to meet clinician needs at the bedside and for their research purposes.
He graduated from Melbourne University Medical School, Victoria, Australia, in 1980, and completed fellowships in anesthesia and pediatric critical care medicine. He has the good fortune of working on staff at 3 major pediatric hospitals across the world, Royal Children’s Hospital, Melbourne(1989-1992), Boston Children’s Hospital (1992-2012), and The Hospital for Sick Children, Toronto (2012 to present). His professional interests focus on the use of continuous physiologic data for predictive modeling at Laussen Labs; a diverse team in Toronto conducting research in this area. He has considerable experience in quality, systems and human engineering applied to critical care. In 2006 he was a founding member of Risky Business, a unique forum for discussing risk management in healthcare.